Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study

Conclusions
In this first international prospective study, the composite PDUS score is responsive to abatacept. GLOESS demonstrated the rapid onset of action of abatacept, regardless of the number of joints examined. Ultrasound is an objective tool to monitor patients with RA under treatment.

Trial registration number
NCT00767325.

Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: D'Agostino, M.-A., Wakefield, R. J., Berner-Hammer, H., Vittecoq, O., Filippou, G., Balint, P., Möller, I., Iagnocco, A., Naredo, E., Ostergaard, M., Boers, M., Gaillez, C., Van Holder, K., Le Bars, M., on behalf of the OMERACT-EULAR-Ultrasound Ta Tags: Open access, Immunology (including allergy), Radiology, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Clinical diagnostic tests, Radiology (diagnostics) Clinical and epidemiological research Source Type: research